Phathom Pharmaceuticals Inc —— 财务报表 (NASDAQ:PHAT) | MetaTrader

展开完整图表

新闻

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

古根海姆上调Phathom股票目标价至25美元,因营收超预期

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Stifel重申Phathom股票买入评级,维持28美元目标价

Stifel reiterates Buy on Phathom stock, keeps $28 price target

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates